Dimensional Fund Advisors LP Has $860.70 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Dimensional Fund Advisors LP has decreased its holdings in Thermo Fisher Scientific Inc. by 9.0%, owning 1,729,682 shares valued at approximately $860.7 million.
• Analyst ratings for Thermo Fisher are mixed, with Raymond James maintaining an "outperform" rating and an upgraded target price of $535, while Evercore ISI and other firms lowered their target prices.
• Thermo Fisher announced a quarterly dividend of $0.43 per share, yielding 0.4%, with a payout ratio of 9.95% and an upcoming ex-dividend date of September 15th.

Dimensional Fund Advisors LP reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,729,682 shares of the medical research company's stock after selling 170,141 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.46% of Thermo Fisher Scientific worth $860,695,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after acquiring an additional 2,415,346 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after buying an additional 1,433,444 shares during the period. Nuveen LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $532,360,000. Kovitz Investment Group Partners LLC boosted its position in shares of Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after buying an additional 858,193 shares during the period. Finally, Farallon Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 73.8% in the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after buying an additional 523,800 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 8,000 shares of the firm's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $454.45, for a total value of $3,635,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,340,824.30. This represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,400 shares of company stock valued at $8,345,792. Corporate insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TMO shares. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Royal Bank Of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Finally, HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Performance

TMO traded up $4.92 during trading hours on Friday, hitting $489.96. The company's stock had a trading volume of 2,462,453 shares, compared to its average volume of 3,059,810. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $185.01 billion, a PE ratio of 28.34, a PEG ratio of 2.61 and a beta of 0.74. The company has a 50-day simple moving average of $434.83 and a 200 day simple moving average of $459.02.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the firm earned $5.37 EPS. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.